
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:03:54 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016 | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/26/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/26/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="https://covid-19.hbs.hu" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/262679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1298</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="26">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="26">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/ruT"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Interstitial%20Cystitis-Associated%20Urinary%20Metabolites%20Identified%20by%20Mass-Spectrometry%20Based%20Metabolomics%20Analysis.%202016&amp;url=https://hbs.hu/r/ruT"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/ruT&amp;title=Interstitial%20Cystitis-Associated%20Urinary%20Metabolites%20Identified%20by%20Mass-Spectrometry%20Based%20Metabolomics%20Analysis.%202016&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/ruT"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/26?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="26" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>9. www.nature.com/scientificreports/ 9 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 This work is licensed under a Creative Commons Attribution 4.0 International License. The images  or other third party material in this article are included in the article’s Creative Commons license,  unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license,  users will need to obtain permission from the license holder to reproduce the material. To view a copy of this  license, visit http://creativecommons.org/licenses/by/4.0/   © The Author(s) 2016 </p>
                                        
                                            <p>5. www.nature.com/scientificreports/ 5 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 metabolites are listed in Table 1. This metabolic fingerprint might be applicable to segregate IC patients from  healthy controls in the clinical setting, although it is out of scope of this study. Urine analysis is certainly challenging due to its high biological variance, because urine is a sink for all water  soluble metabolites coming from food sources, the microbiome, drugs, chemicals and generally the exposome.  However urine can be collected non-invasively, across all age ranges and in large quantities compared to blood, it  is also an excellent matrix for personalized clinical profiles. For robust statistical analysis many confounding factors such as age, race, geographical location or food intake  have to be considered. Subject meta-data may be collected through questionnaires at time of sample collection in  the clinic, but it can also be assessed through thorough chemical profiling analyses, called exposome screening  (e.g. for pharmaceutical agents or food biomarkers). For example the compound 2-furoylglycine can be used to  diagnose fatty acid beta-oxidation disorders, but is also found in food prepared by strong heating (http://www. hmdb.ca/metabolites/HMDB00439). Cotinine is a known marker for exposure to cigarette smoke, and other  metabolites are known food markers such as caffeine and theobromine for coffee consumption. Such markers can  be easily collected along with metabolomic analyses and could be used to stratify patient cohorts or to adjust for  exposure parameters during data analysis. Urine metabolite levels are currently collected from published reports 18 . However individual urinary metab - olite levels are currently not collected in large databases. Therefore it is difficult to determine minimum, mean,  maximum levels of specific metabolites or to perform correlations to dietary intake, which would affect the valid - ity of certain biomarkers. Here efforts have to be undertaken to collect such profiles, similar to personalized  efforts that will sequence individual humans or collect individual metabolic profiles from blood. In summary, our GC-TOF MS analysis suggested a number of metabolite candidates associated with IC. Large  cohorts have to be utilized to validate predictive biomarkers or models. This method may provide novel opportu - nities for better diagnosis and clinical management of IC, particularly in a non-invasive manner. A major clinical  challenge remains the early diagnosis of IC. Given that these current findings from this study, although it is out  of scope of this study, however we will aim to test whether abnormal metabolism is a key hallmark of IC as a next  step. Our metabolic biomarker panel provides the prospect for assisting predictive factor to determine severity of  urinary symptoms and pain/discomfort of IC patients. Num Name Fold-change p-value FDR 1 Unknown BB_31554 2.56 0.000132 0.064576 2 Unknown BB_34163 0.55 0.000514 0.12586 3 oleic acid 0.63 0.001933 0.315675 4 2-deoxytetronic acid 1.26 0.008732 0.571396 5 Unknown BB_17651 0.66 0.009136 0.571396 6 saccharic acid 0.80 0.012642 0.571396 7 Unknown BB_17140 1.44 0.015588 0.571396 8 phosphate 0.70 0.016252 0.571396 9 trehalose 1.79 0.017026 0.571396 10 Unknown BB_5900 0.81 0.017487 0.571396 11 erythronic acid 2.25 0.018393 0.571396 12 Unknown BB_109809 0.56 0.018576 0.571396 13 oxalic acid 0.48 0.018665 0.571396 14 Unknown BB_34027 0.44 0.019904 0.571396 15 Unknown BB_1704 0.63 0.020865 0.571396 16 sulfuric acid 0.31 0.021197 0.571396 17 Unknown BB_23635 0.69 0.02138 0.571396 18 cystine 1.47 0.021607 0.571396 19 Unknown BB_3029 0.70 0.022156 0.571396 20 Unknown BB_12330 2.19 0.02596 0.614149 21 Unknown BB_31549 0.37 0.026702 0.614149 22 lyxitol 1.42 0.028288 0.614149 23 Unknown BB_31756 1.74 0.028827 0.614149 24 lysine 1.49 0.034624 0.706901 25 histidine 1.79 0.040576 0.743323 26 Unknown BB_31359 0.81 0.043988 0.743323 27 Unknown BB_5121 0.64 0.045462 0.743323 28 Unknown BB_100869 1.58 0.046685 0.743323 29 Unknown BB_3294 1.37 0.046907 0.743323 30 Unknown BB_31764 1.33 0.048566 0.743323 Table 1.    A list of metabolites differentially expressed in IC, compared to controls (p-level   =   0.005,  FDR  (Benjamini Hochberg). </p>
                                        
                                            <p>6. www.nature.com/scientificreports/ 6 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 Materials and Methods Ethics statement.   The Ethics Committee of Inha University Hospital in South Korea approved this study.  The Institutional Review Board of Inha University Hospital approved collection, curation and analysis of all sam - ples. All subjects participated in this study provided written informed consent, and all experiments were per - formed in accordance with relevant guidelines and regulations. Subjects and urine specimen collection.   IC patients and healthy control subjects were diagnosed and  recruited from an outpatient urology clinic at Inha University Hospital. Work-up included symptom assessment,  cystoscopic evaluation, physical examination, urodynamics, and/or urine culture. Patients with a history of other  diseases (such as any types of cancer, inflammation, or diabetes, etc.) were excluded. All subjects were of Asian  female descent resident in South Korea. To avoid possible contamination with vaginal or urethral cells, first  morning urine specimens were obtained using clean catch methods in a sterile environment. The de-identified  specimens were sent to clinical laboratory and were centrifuged to remove cell debris. Supernatants were pro - cessed into individual aliquots of 1   ml/tube, before storage at  −   80   °C until further analysis. GC TOF-MS analysis of urine.   The gas-chromatography/mass-spectrometry (GC-MS) analysis was    performed 19 ,20 . Normally, 10   ul of urine are dissolved in 1   ml  −   20   °C cooled acetonitrile, isopropanol and water  (3:3:2   v/v) mixture at pH 7. In this case the urine volume was adjusted between 2 and 10   ul to externally measured  creatinine levels using a linear calibration curve. Then the solution was vortexed at 4   °C for 5   minutes in 1.5   ml  Eppendorf tubes. Samples were centrifuged for 2   min at 14,000 rcf and 500   ul were aliquoted. The aliquot was  the evaporated in a Labconco Centrivap cold trap to complete dryness. The methoximation step was performed  with 10   ul of a solution of 40   mg/ml O-methylhydroxylamine hydrochloride (CAS: [593-56-6]; Formula CH5NO. HCl) and 90   minutes shaking at 30   °C. Then 90   ul of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was  added and shaken at 37   °C for 30   min. Then a mix of 1   ul fatty acid methyl esters (FAME) retention time markers  was added. The mixture was transferred to amber crimp autosampler vials. Measurements were performed on a  Leco Pegasus IV TOF coupled to an Agilent 6890GC with Agilent 6890 split/splitless injector. The column was a  Restek RTX-5Sil MS (95% dimethyl/5% diphenyl polysiloxane) with 30   m length, 0.25   mm i.d. and 0.25   um film  thickness with 10   m guard column. Injection volume was 1   ul at 250   °C. The GC parameters were set to 1   ml/min    constant flow Helium and an oven ramp of 50   °C (1   min hold) to 330   °C at 20   °C/min, 5   min hold before  cool-down. The transfer line temperature was 280   °C and spectra were recorded in electron ionization mode at  70   eV with a filament temperature of 250   °C TOF and scan range of 85–500   u. All the raw data was deposited to  the Metabolomics Workbench repository under study ID ST000381. Figure 3.   Network modeling derived from IC-associated metabolites.  Histidine associated differential  module (subnetwork) is shown, where the red nodes indicate upregulated metabolites and light blue nodes  represents non-differentiated metabolites. </p>
                                        
                                            <p>3. www.nature.com/scientificreports/ 3 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 Discussion In this study we profiled 490 metabolites in human urine specimens for IC diagnosis using GC-TOF MS.  Metabolites including histidine, erythronic acid, and tartaric acid were found to have the highest fold-changes.  Power analysis and false discovery rate correction (FDR, Benjamini-Hochberg) suggests that the study sample  size has to be increased to validate any findings. The present report has provided evidence that metabolic finger - prints can predict IC patients using multiparametric models such as PLS-DA, however it remains to be deter - mined whether these metabolites might have biological and mechanistic meanings. Especially the large number  of unknown compounds is challenging (59% in this study), because without structural annotation, unnknown  metabolites can only be partly assigned to larger biochemical modules through mass spectral similarity analysis.  Some unknowns may even ultimately prove to be chemical contaminants and should be excluded from multipar - ametric models. One solution to increase mass spectral library coverage is to use quantum chemical simulations  Figure 1.   Differentiation of IC patients and healthy control groups using multivariate analysis.  ( A ) Partial  least square-discriminant analysis (PLS-DA) score plot of the IC and control groups. PLS-DA plot showed a  clear separation of metabolites between patients and matched control subjects. Red: control samples; Green:  IC patient samples. The model was established using three principal components. ( B ) For model evaluation,  the class prediction results based on cross model validation predictions of the original labeling compared to  the permuted data assessed using the separation distance. Histogram shows distribution of separation distance  based on permutated data. Red arrow indicates observed statistic (P   =    5e-04).  ( C ) A heatmap of 52 differentially  expressed metabolites in IC and control groups. Among 490 detected metabolites in total, 52 metabolites,  including both annotated and unannotated metabolites, were significantly altered in IC patients compared to  controls (FC   &gt;    1.20 or FC   &lt;    0.83 and P   &lt;    0.1). </p>
                                        
                                            <p>7. www.nature.com/scientificreports/ 7 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 Annotation and ID of compounds.   The peak and compounds detection or deconvolution was performed  with the Leco ChromaTOF software. Spectra were matched against the FiehnLib mass spectral and retention  index library 20 . Post-curation and peak replacements were performed with the in-house developed BinBase soft - ware and the sample matrix with all known and unknown compounds exported to a Microsoft EXCEL sheet. A  total of 490 compounds were detected. 200 compounds were annotated as known compounds by retention index  and mass spectral matching and 290 compounds remain unknown. Data processing.   We excluded one subject from the IC patient group and three subjects from controls  because their spectra were outliers based on PCA analysis. To identify potential metabolites as marker candidates  that can discriminate IC patients from healthy subjects, we applied the following steps. Data was normalized and  the t-test was applied on the log2 of the processed data. The Student’s t-test was performed to extract significant  metabolites from the normalized GC-MS data. 30 metabolites had levels of  p -value threshold   &lt; 0.05. Twelve of  these were known metabolites, the remainder unknown metabolites. After false positive correction (FDR) using  Benjamini–Hochberg procedure none of the p-values remained significant on the chosen level of 0.05. The volcano plot shows the fold change and the significance of each annotated metabolite. The significant  metabolites were selected by volcano plot with fold change threshold  &gt;   1.20  (or   &lt; 0.83) and t-tests  p -value  threshold  &lt;   0.1. Second, the resultant profiles, which contain profiles of 22 annotated differentially expressed  metabolites, were imported into MetaboAnalyst version 3.0 1 . Log transformation and mean-centered with  auto scaling were performed prior to multivariate statistical analysis. Partial least square discriminant analysis  (PLS-DA) was performed, and model evaluation with permutation strategy was carried out according to a  published protocol 21 . Figure 4.   Differential network in IC is identified with multilevel local graphical model 7 . The differential  network represents the changes of correlation structure in IC when compared to the background network.  Two metabolites (in red) are also upregulated in IC. The interactions (correlations) among metabolites indicate  those metabolites may function together biologically. Metabolite Set Enrichment Analysis (MESA) with the 18  metabolites shows that those metabolites are highly enriched in Protein Biosynthesis and Ammonia Recycling  with the FDR of 0.0000136 and 0.00557, respectively. The following is the result of MSEA. </p>
                                        
                                            <p>4. www.nature.com/scientificreports/ 4 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 predict electron ionization mass spectra 9  or to utilize novel machine learning methods to improve compound  identification 10 . This can also include novel metabolic compounds that can be expected to exist from known  metabolic transformations 11 . Histidine, one of essential amino acids in humans, is a known precursor of the neurotransmitter histamine.  Increased histidine level leads to increase of histamine level in blood, brain and possibly bladder, suggesting  the possibility that histidine may have many other possible functions affecting human bladder sensory system.  Previous work using IC rat model demonstrated that overexpression of monocyte chemo-attractant protein-1  (MCP-1) in bladder tissues contributes histamine production and IC 12 . More recently, findings from animal  model suggest that mast cell-derived histamine mediates IC-associated pain. Authors showed that histamine  receptors 1 and 2 modulate pelvic pain and antihistamines attenuate bladder pain in their animal model. We  believe the simplest explanation for this finding is that an increased secretion of histamine and histidine (pre - cursor of histamine) may be associated with IC symptoms mediated by mast cells infiltrated in bladder. Other  candidate metabolites from our study are summarized in Table 1. Previous studies have suggested a series of IC biomarker candidates, including antiproliferative factor 13 ,    phenylacetylglutamine 14 , interleukin-6, histamines 15 , nerve growth factor  et al.  Our laboratory also found  tyramine and 2-oxoglutarate as urinary biomarkers for IC diagnosis 16 . More recently, the Multidisciplinary    Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network identified Etio-S (etiocholan-3 α   -ol-17   -one sulfate) to discriminate IC patients from healthy controls 17 . This urinary sulfometabolome profiling study  was performed using Liquid Chromatography–Mass Spectrometry (LC–MS) in female subjects who had high  symptom scores as well as high pelvic pain/pressure/discomfort scores. Metabolic fingerprints shown in a heatmap (Fig. 1C) consist of 22 annotated metabolites among 52 metab - olites shown in a heatmap (Fig. 1C) including histidine, valine, tartaric acid, and erythronic acid  et al.  These  Figure 2.   A volcano plot showing differentially expressed metabolites in IC patients.  ( A ) 22 annotated  metabolites were significantly altered in IC patients compared to controls (FC   &gt;    1.20 or FC   &lt;    0.83 and P   &lt;    0.1).  The red dots represent metabolites above the threshold. The further the metabolite’s position away from the    (0, 0), the more significant the metabolite is. ( B ) A boxplot showing up-regulated and down-regulated  metabolites that could be used to differentiate IC patients from normal subjects. The candidate metabolites,  erythronic acid and histidine, were significantly increased in IC patients compared to that in controls, while  tartaric acid was significantly decreased. All metabolites show statistical significance with p-value   &lt;    0.1. </p>
                                        
                                            <p>1. 1 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 www.nature.com/scientificreports Interstitial Cystitis-Associated  Urinary Metabolites Identified  by Mass-Spectrometry Based  Metabolomics Analysis Tobias   Kind 1 , Eunho   Cho 2 , Taeeun   D.   Park 3 , Nan   Deng 4 , Zhenqiu   Liu 4 , Tack   Lee 5 ,  Oliver   Fiehn 1 , 6  &amp; Jayoung   Kim 2 , 4 , 7 , 8 This study on interstitial cystitis (IC) aims to identify a unique urine metabolomic profile associated with  IC, which can be defined as an unpleasant sensation including pain and discomfort related to the urinary  bladder, without infection or other identifiable causes. Although the burden of IC on the American  public is immense in both human and financial terms, there is no clear diagnostic test for IC, but rather  it is a disease of exclusion. Very little is known about the clinically useful urinary biomarkers of IC,  which are desperately needed. Untargeted comprehensive metabolomic profiling was performed using  gas-chromatography/mass-spectrometry to compare urine specimens of IC patients or health donors.  The study profiled 200 known and 290 unknown metabolites. The majority of the thirty significantly  changed metabolites before false discovery rate correction were unknown compounds. Partial least  square discriminant analysis clearly separated IC patients from controls. The high number of unknown  compounds hinders useful biological interpretation of such predictive models. Given that urine analyses  have great potential to be adapted in clinical practice, research has to be focused on the identification of  unknown compounds to uncover important clues about underlying disease mechanisms. More than 3–8 million women and 1–4 million men are diagnosed with Interstitial Cystitis (IC), also known  as Painful Bladder Syndrome, in the US annually 1 . IC impacts health-related qualities of life immensely, and in  some instances can be more debilitating than end-stage renal disease 2 ,3 . In spite of an increase in the number of  diagnosed cases, objective diagnostic criteria are not consistently applied in general practice 4 . Some lower urinary  tract symptoms, such as overactive bladder (OAB), have symptoms in common with IC, further complicating the  diagnosis. Diagnosis of the disease has been dependent on clinical parameters (e.g. pain, urgency, and frequency)  due to the lack of proper conventional markers (e.g. PSA for prostate cancer diagnosis) 3 ,5 . Diagnostic tests include  urinalysis, urine culture, cystoscopy, bladder biopsy and hydrodistention of the bladder. Nonetheless, we still lack  definite criteria for the disease. Estimates of the prevalence and natural history of IC still fluctuate widely because  of different diagnostic standards, populations evaluated, and challenges inherent in following patients over time 6 .  Thus, the identification of sensitive and non-invasive biomarkers has the potential to greatly improve the accuracy  of an IC diagnosis. However, our current understanding of mechanisms involving pelvic pain is also unclear and  fragmented. Urinary metabolites represent a signature of a subject’s metabolic state and may convey critical information  about the pathophysiology of disease. This may be especially true for pelvic disorders because urine is the body  fluid most proximal to the urinary tract. Because metabolites vary in size, chemistry and physicochemical prop - erties, a single platform has only a limited capacity to interrogate the entire metabolome in a given body fluid. Use  of more than one platform spanning different technologies is the preferred means of performing comprehensive  1 West Coast Metabolomics Center, University of California, Davis, Davis, CA, USA.  2 University of California Los  Angeles, CA, USA.  3 University of California, Berkerly, CA, USA.  4 Samuel Oschin Comprehensive Cancer Institute,  Cedars-Sinai Medical Center, Los Angeles, CA, USA.  5 Department of Urology, Inha University College of Medicine,  Incheon, South Korea.  6 King Abdulaziz University, Jeddah, Saudi Arabia.  7 Departments of Surgery and Biomedical  Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.  8 Department of Medicine, University of California  Los Angeles, Los Angeles, CA, USA. Correspondence and requests for materials should be addressed to J.K. (email:  <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="541e352d3b213a337a1f3d391437273c277a3b2633">[email&#160;protected]</a>) r eceived: 22 August 2016 A ccepted: 18 November 2016 P ublished: 15 December 2016 OPEN </p>
                                        
                                            <p>2. www.nature.com/scientificreports/ 2 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 metabolome analyses. Urine excretions represent a snapshot of many metabolic endpoints including those from  food, drugs, nutrients and bacterial transformations. This renders urine analysis very challenging due to the com - plexity, sources and numbers of metabolites. In this study, we performed gas-chromatography time of flight mass spectrometry (MS)-based metabolomics  analysis. Our goal here was to increase coverage of known metabolites that may play a role in IC and to gain new  insight into disease mechanisms. Previous global metabolomics profiling of urine from IC patients suggests that a  urinary metabolic signature for IC can be detected using platforms such as Nuclear Magnetic Resonance (NMR)  and Liquid chromatography–mass spectrometry (LC-MS). The experimental results from this paper suggest that  candidate metabolites were found to be associated with IC, and that the IC metabolic signature can be identified  in patient urine. Using multiparametric models such partial least squares discriminant analysis IC metabolic  signature can stratify patients from control subjects. Results Characteristics of the study subjects.   A clinical diagnosis of IC was made by two independent urolo - gists, according to NIDDK criteria (e.g. frequency, urgency, bladder pain, discomfort and the presence of glo - merulations during cystoscopic hydrodistention), before any treatment or medication was given. Only subjects  of  &gt;   2 month “free of treatment or medication” were included. In total, we enrolled 63 female subjects (42 IC  patients and 21 normal controls) with a mean age of 51. Given that most of patients (over 80%) are women, we  recruited only female patients for this particular study to seek potential sex-specific urine biomarkers for female  IC patients. Population-based, age-matched controls were recruited from one clinic using the same standard  operating procedures (SOPs) during the same research period (2010–2013). GC-TOF MS analysis of urine specimens from IC patients and controls.   We investigated the metab - olite profile of the individual urine samples using GC-TOF mass spectrometry. Our analysis and data requisition  resulted in a total of 490 metabolites detected (200 known and 290 unknown metabolites). Data were autoscaled and mean-centered. The scores plot for partial least squares (PLS) components showed  differentiation of the IC samples from controls with good separation and dispersion (Fig. 1A). We assessed the  accuracy of our predictive model using the leave-one-out cross-validation method as well as the randomized  permutation (Fig. 1B). The observed statistic of this analysis using MetaboAnalyst 3.0 software 1  was significant  at p   =    0.005, suggesting that the model significantly differentiate patients from healthy controls. A heat map also  showed the distinct expression patterns of metabolites between IC and controls (Fig. 1C). These metabolites are  responsible for the significant difference between IC and controls with fold change either greater than 1.20 or less  than 0.83 and p-value less than 0.1. Identification of differentially expressed metabolites in urine of IC patients.   Given 490 detected  metabolites, we investigated 52 differentially expressed metabolites, including both annotated and unannotated  metabolites. In the volcano plot (Fig. 2A), annotated metabolites are presented as log2 fold change against the  –log10 (p) of the differential expression between IC patients and healthy controls. 22 annotated differentially  expressed metabolites above the threshold (FC   &gt;    1.20 or FC   &lt;    0.83, and P   &lt;    0.1) are marked and presented.  Erythronic acid and histidine, were the most upregulated metabolites in the IC patient group compared to that in  control, while tartaric acid were the most downregulated as shown in Fig. 2B and Table 1. Network modeling derived from IC-associated metabolites.   We performed analysis the histidine-   associated differential module (subnetwork) using multilevel local graphical model 7  (Fig. 3). The differential    network represents the changes of correlation structure in IC when compared to the background network. Levels  of two metabolites, valine and histidine (in red circle), are increased in IC. The interactions (correlations) among  metabolites indicate that those metabolites may biologically function together. Generally, the variations of inter - actions among metabolites under different clinical conditions are associated with IC status. Sparse local graphical  model 8  is used to construct both common and differential metabolite networks simultaneously. Treating each  metabolite, in turn, as the response variable and the remaining annotated metabolites as predictors, and running  the sparse regression built the network. In such an approach, for each metabolite  x i , the regression model is  defined as αβ ε =+ + −− xX yX , ii ii ii where  X − i  are the metabolite expression values except for metabolite  x i , and  y  (1/0) represents IC (1) or control  (0). The common and differential networks are formed by collecting all of the  α i s  and  β i s , respectively. Parameters  ( α i ) determine the direct correlations between metabolite  x i  and the remaining metabolites, and  α ij   ≠    0  indicate  there is a partial correlation (edge) between metabolites  x i  and  x j , giving the remaining metabolites. Moreover,  β i  measure  y  dependent associations and differential correlations across different clinical condition. Parameter  β ij   ≠    0 indicates that there is a differential interaction between metabolites  x i  and  x j  in IC and control. Cytoscape (www.cytoscape.org/) was used for differential network visualization and subnetwork identifica - tion. The proposed approach identified the IC associated differential network efficiently (Fig. 3). For further  understanding on our metabolite signature, software MetaboAnalyst was used for functional enrichment analysis.  Metabolite enrichment analysis allows us to study the corresponding biological pathways of IC with metabolites  on the differential network. We performed Metabolite Set Enrichment Analysis (MSEA) with the 18 metabo - lites, which were derived from data in Fig. 3. We found that those 18 metabolites are highly enriched in Protein  Biosynthesis and Ammonia Recycling with the FDR of 0.0000136 and 0.00557, respectively (Fig. 4). </p>
                                        
                                            <p>8. www.nature.com/scientificreports/ 8 Scientific   Repo R ts  | 6:39227 | DOI: 10.1038/srep39227 References 1.   Berry, S. H.  et al.  Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States.  The Journal of urology   186,  540–544, doi: 10.1016/j.juro.2011.03.132 (2011). 2.   Hanno, P. M.  et al.  AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome.  The Journal of  urology   185,  2162–2170, doi: 10.1016/j.juro.2011.03.064 (2011). 3.   Winters, J. C.  et al.  Urodynamic studies in adults: AUA/SUFU guideline.  The Journal of urology   188,  2464–2472, doi: 10.1016/j. juro.2012.09.081 (2012). 4.   Hanno, P., Keay, S., Moldwin, R. &amp; Van Ophoven, A. International Consultation on IC - Rome, September 2004/Forging an  International Consensus: progress in painful bladder syndrome/interstitial cystitis. Report and abstracts.  International urogynecology  journal and pelvic floor dysfunction   16  Suppl 1, S2–S34, doi: 10.1007/s00192-005-1301-x (2005). 5.   Clemens, J. Q.  et al.  Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary  pain in both men and women.  Urology   74,  983–987, quiz 987 e981–983, doi: 10.1016/j.urology.2009.06.078 (2009). 6.   Stephens-Shields, A. J.  et al.  Symptom Variability and Early Symptom Regression in the MAPP Study: A Prospective Study of  Urological Chronic Pelvic Pain Syndrome.  The Journal of urology   196,  1450–1455, doi: 10.1016/j.juro.2016.04.070 (2016). 7.   Liu, Z.  et al.  Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased  stromal activation.  Gynecologic oncology   139,  394–400, doi: 10.1016/j.ygyno.2015.08.026 (2015). 8.   Liu, Z., Sun, F., Braun, J., McGovern, D. P. &amp; Piantadosi, S. Multilevel regularized regression for simultaneous taxa selection and  network construction with metagenomic count data.  Bioinformatics   31,  1067–1074, doi: 10.1093/bioinformatics/btu778 (2015). 9.   Grimme, S. Towards first principles calculation of electron impact mass spectra of molecules.  Angewandte Chemie   52,  6306–6312,  doi: 10.1002/anie.201300158 (2013). 10.   Allen, F., Pon, A., Greiner, R. &amp; Wishart, D. Computational Prediction of Electron Ionization Mass Spectra to Assist in GC/MS  Compound Identification.  Analytical chemistry   88,  7689–7697, doi: 10.1021/acs.analchem.6b01622 (2016). 11.   Jeffryes, J. G.  et al.  MINEs: open access databases of computationally predicted enzyme promiscuity products for untargeted  metabolomics.  Journal of cheminformatics   7,  44, doi: 10.1186/s13321-015-0087-1 (2015). 12.   Lv, J.  et al.  MCP-1-induced histamine release from mast cells is associated with development of interstitial cystitis/bladder pain  syndrome in rat models.  Mediators of inflammation   2012,  358184, doi: 10.1155/2012/358184 (2012). 13.   Erickson, S.  et al.  Interferon-alpha inhibits Stat5 DNA-binding in IL-2 stimulated primary T-lymphocytes.  European journal of  biochemistry/FEBS   269,  29–37 (2002). 14.   Fukui, Y., Kato, M., Inoue, Y., Matsubara, A. &amp; Itoh, K. A metabonomic approach identifies human urinary phenylacetylglutamine  as a novel marker of interstitial cystitis.  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences   877,   3806–3812, doi: 10.1016/j.jchromb.2009.09.025 (2009). 15.   Lamale, L. M., Lutgendorf, S. K., Zimmerman, M. B. &amp; Kreder, K. J. Interleukin-6, histamine, and methylhistamine as diagnostic  markers for interstitial cystitis.  Urology   68,  702–706, doi: 10.1016/j.urology.2006.04.033 (2006). 16.   Wen, H.  et al.  Urinary metabolite profiling combined with computational analysis predicts interstitial cystitis-associated candidate  biomarkers.  Journal of proteome research   14,  541–548, doi: 10.1021/pr5007729 (2015). 17.   Parker, K. S.  et al.  Urinary Metabolomics Identifies a Molecular Correlate of Interstitial Cystitis/Bladder Pain Syndrome in a  Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network Cohort.  EBioMedicine   7,  167–174,    doi: 10.1016/j.ebiom.2016.03.040 (2016). 18.   Bouatra, S.  et al.  The human urine metabolome.  PloS one   8,  e73076, doi: 10.1371/journal.pone.0073076 (2013). 19.   Kind, T., Tolstikov, V., Fiehn, O. &amp; Weiss, R. H. A comprehensive urinary metabolomic approach for identifying kidney cancerr.  Analytical biochemistry   363,  185–195, doi: 10.1016/j.ab.2007.01.028 (2007). 20.   Kind, T.  et al.  FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas  chromatography/mass spectrometry.  Analytical chemistry   81,  10038–10048, doi: 10.1021/ac9019522 (2009). 21.   Xia, J., Sinelnikov, I. V. &amp; Wishart, D. S. MetATT: a web-based metabolomics tool for analyzing time-series and two-factor datasets.  Bioinformatics   27,  2455–2456, doi: 10.1093/bioinformatics/btr392 (2011). Acknowledgements The authors acknowledge support from National Institutes of Health (1U01DK103260, 1R01DK100974, U24  DK097154, NIH NCATS UCLA CTSI UL1TR000124), Department of Defense (W81XWH-15-1-0415), Centers  for Disease Controls and Prevention (1U01DP006079), IMAGINE NO IC Research Grant, the Steven Spielberg  Discovery Fund in Prostate Cancer Research Career Development Award, the U.S.-Egypt Science and Technology  Development Fund by the National Academies of Sciences, Engineering, and Medicine (all to J.K.), and Inha  University Research grant (INHA-50487 (to T.L.)). J.K. is former recipient of Interstitial Cystitis Association Pilot  Grant, a Fishbein Family IC Research Grant, New York Academy of Medicine, and Boston Children’s Hospital  Faculty Development. Funding for T.K. and O.F. was supported by NSF MCB1139644, NSF MCB1611846, NIH  P20HL113452 and U24DK097154. Additional funding for T.K. was provided by the American Heart Association  15SDG25760020 and NIH 2R01HL091357-05. The funders had no role in the design, data collection and analysis,  decision to publish or preparation of the manuscript. Author Contributions J.K., O.F., and T.L. designed the study, led obtaining funding, and overviewed the literature analysis and drafting  the manuscript. T.K., E.C., and T.D.P. performed metabolomics analysis and sample preparation. N.D., and Z.L.  performed data analysis and visualize the data. T.K., E.C., T.D.P., N.D., and Z.L. helped writing the manuscript.  All authors read and approved the final manuscript. Additional Information Competing financial interests:  The authors declare no competing financial interests. How to cite this article:  Kind, T.  et al.  Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass- Spectrometry Based Metabolomics Analysis.  Sci. Rep.   6 , 39227; doi: 10.1038/srep39227 (2016). Publisher's note:  Springer Nature remains neutral with regard to jurisdictional claims in published maps and  institutional affiliations. </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1298</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">987</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">311</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    3
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">10</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">6</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1472 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1384 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1463 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1303 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1361 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1412 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1366 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1219 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1386 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1249 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1309 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1357 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/37/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections- bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1239 Views . <timeago class="timeago" datetime="2019-10-31 13:46:36.042595"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1773 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1618 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="355c5b535a755d57461b5d40">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <!--<div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>-->

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:03:58 GMT -->
</html>
    
    
